BR0317392A - Formulação não-higroscópica incluindo uma droga higroscópica - Google Patents
Formulação não-higroscópica incluindo uma droga higroscópicaInfo
- Publication number
- BR0317392A BR0317392A BR0317392-5A BR0317392A BR0317392A BR 0317392 A BR0317392 A BR 0317392A BR 0317392 A BR0317392 A BR 0317392A BR 0317392 A BR0317392 A BR 0317392A
- Authority
- BR
- Brazil
- Prior art keywords
- hygroscopic
- drug
- formulation including
- polymer
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
"FORMULAçãO NãO-HIGROSCóPICA INCLUINDO UMA DROGA HIGROSCóPICA". A presente invenção refere-se a uma composição sólida em partículas, que inclui uma droga higroscópica ou deliq³escente e pelo menos um polímero não-higroscópico. A droga e pelo menos um polímero estão intimamente associados, e a composição é aceitavelmente não-higroscópica.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43514702P | 2002-12-19 | 2002-12-19 | |
US43542202P | 2002-12-19 | 2002-12-19 | |
US43502202P | 2002-12-19 | 2002-12-19 | |
PCT/US2003/038792 WO2004060352A1 (en) | 2002-12-19 | 2003-12-05 | Non-hygroscopic formulation comprising a hydroscopic drug |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0317392A true BR0317392A (pt) | 2005-12-20 |
Family
ID=32719157
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0317392-5A BR0317392A (pt) | 2002-12-19 | 2003-12-05 | Formulação não-higroscópica incluindo uma droga higroscópica |
BR0317103-5A BR0317103A (pt) | 2002-12-19 | 2003-12-11 | Dispersões sólidas comprendendo um fármaco higroscópico e/ou deliquescente |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0317103-5A BR0317103A (pt) | 2002-12-19 | 2003-12-11 | Dispersões sólidas comprendendo um fármaco higroscópico e/ou deliquescente |
Country Status (17)
Country | Link |
---|---|
US (2) | US20040197411A1 (pt) |
EP (2) | EP1575563B1 (pt) |
JP (2) | JP2006513238A (pt) |
AR (2) | AR042511A1 (pt) |
AT (1) | ATE353633T1 (pt) |
AU (2) | AU2003298010A1 (pt) |
BR (2) | BR0317392A (pt) |
CA (2) | CA2511385A1 (pt) |
DE (1) | DE60311875T2 (pt) |
ES (1) | ES2280835T3 (pt) |
HN (1) | HN2003000417A (pt) |
MX (2) | MXPA05006802A (pt) |
NL (1) | NL1025069C2 (pt) |
PE (1) | PE20040972A1 (pt) |
TW (2) | TW200423971A (pt) |
UY (1) | UY28138A1 (pt) |
WO (2) | WO2004060352A1 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE327744T1 (de) | 2001-03-20 | 2006-06-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz |
ATE228358T1 (de) | 2001-03-21 | 2002-12-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen |
SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
ATE353633T1 (de) * | 2002-12-19 | 2007-03-15 | Pharmacia Corp | Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält |
DK3473251T3 (da) | 2002-12-20 | 2024-01-22 | Niconovum Ab | Nikotin-cellulose-kombination |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
FR2865133B1 (fr) * | 2004-01-19 | 2008-01-18 | Rytek | Compositions pour le traitement de pathologies digestives |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
WO2005099740A1 (en) | 2004-04-16 | 2005-10-27 | Schwarz Pharma Ag | Use of peptidic compounds for the prophylaxis and treatment of chronic headache |
ATE438390T1 (de) * | 2004-07-02 | 2009-08-15 | Radi Medical Biodegradable Ab | Rauchloses tabakprodukt |
NZ552651A (en) * | 2004-08-27 | 2010-07-30 | Sanol Arznei Schwarz Gmbh | Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
US20060147518A1 (en) * | 2004-12-30 | 2006-07-06 | Pierre Fabre Medicament | Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it |
US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
WO2007060540A1 (en) * | 2005-11-25 | 2007-05-31 | Aurobindo Pharma Limited | Stable dosage forms of an antidepressant |
CA2646942C (en) | 2006-03-16 | 2014-07-29 | Niconovum Ab | Improved snuff composition |
NZ572702A (en) * | 2006-06-06 | 2011-09-30 | Tibotec Pharm Ltd | Process for preparing spray dried formulations of etravirine in microcrystalline cellulose |
DK2462990T3 (en) | 2006-06-15 | 2014-02-17 | Ucb Pharma Gmbh | PHARMACEUTICAL COMPOSITION COMPREHENSIVE LACOSAMIDE AND LEVETIRACETAM WITH SYNERGISTIC ANTI-CONVULSIVE EFFECT |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
ES2496166T3 (es) * | 2006-12-22 | 2014-09-18 | Yuhan Corporation | Dispersión sólida que contiene revaprazán y proceso para la preparación de la misma |
CN101842318A (zh) * | 2007-08-30 | 2010-09-22 | 普瑞利夫公司 | 用于治疗和预防呼吸疾病或病症的甘油磷酸钙 |
US9358242B2 (en) * | 2007-08-30 | 2016-06-07 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
KR101499533B1 (ko) * | 2008-02-15 | 2015-03-09 | 주식회사 씨티씨바이오 | 콜린 알포세레이트 함유 약학 제제 |
DE102008020701A1 (de) * | 2008-04-24 | 2009-10-29 | Bayer Technology Services Gmbh | Formulierung mit reduzierter Hygroskopizität |
DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
KR101172699B1 (ko) | 2011-05-16 | 2012-08-09 | 한국프라임제약주식회사 | 콜린알포세레이트를 함유하는 약학 제제, 및 그의 제조방법 |
EP2729555A1 (en) | 2011-07-07 | 2014-05-14 | The Lubrizol Corporation | Lubricant providing improved cleanliness for two-stroke cycle engines |
CN102525992A (zh) * | 2012-03-09 | 2012-07-04 | 徐奎 | L-α-甘油磷酸胆碱薄膜衣片及其制备方法 |
HUE060093T2 (hu) | 2012-03-15 | 2023-01-28 | Boehringer Ingelheim Vetmedica Gmbh | Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása |
US20150141457A1 (en) * | 2012-05-21 | 2015-05-21 | Hetero Research Foundation | Elvitegravir solid dispersion |
WO2015007760A1 (en) | 2013-07-19 | 2015-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
CA3176466A1 (en) * | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
GB2525170A (en) * | 2014-04-07 | 2015-10-21 | Nokia Technologies Oy | Stereo viewing |
CN104739776A (zh) * | 2015-04-15 | 2015-07-01 | 福州乾正药业有限公司 | 左卡尼汀的固体分散体组合物及其制备方法和药物应用 |
WO2017013591A1 (en) * | 2015-07-22 | 2017-01-26 | Leiutis Pharmaceuticals Pvt Ltd | Stabilized liquid formulation of levothyroxine |
MX2018011348A (es) * | 2016-03-18 | 2019-07-12 | Brian Reid Christopher | Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades. |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
CN111902422A (zh) * | 2018-03-30 | 2020-11-06 | 株式会社钟化 | 含有氧化型谷胱甘肽的固体组合物及其制造方法 |
CN112316678A (zh) * | 2020-10-12 | 2021-02-05 | 常州市永勃机械有限公司 | 一种变电站柜体用驱潮剂制备工艺制备方法 |
IT202100018578A1 (it) * | 2021-07-14 | 2023-01-14 | Indena Spa | Dispersione amorfa di maltolo ferrico e relativo processo di preparazione |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4835187A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
JPH02218621A (ja) * | 1989-02-20 | 1990-08-31 | Nippon Chemiphar Co Ltd | 徐放性製剤 |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
SE9303574D0 (sv) * | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method the manufacturing thereof |
US5688510A (en) * | 1993-11-18 | 1997-11-18 | Nippon Shinyaku Co. Ltd. | Process for producing stable medicinal composition, and pharmaceutical preparation |
JPH08157392A (ja) * | 1994-12-01 | 1996-06-18 | Kanegafuchi Chem Ind Co Ltd | 放出制御型製剤 |
GB9607955D0 (en) * | 1996-04-17 | 1996-06-19 | Tillotts Pharma Ag | Hydrophobic carbomer salt compositions |
JPH10182448A (ja) * | 1996-12-24 | 1998-07-07 | Zensei Yakuhin Kogyo Kk | 圧縮製剤用組成物の製造方法 |
MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
CA2402199C (en) * | 2000-03-24 | 2010-08-03 | Pharmacia Corporation | Amidino compounds useful as nitric oxide synthase inhibitors |
US20020143058A1 (en) * | 2001-01-24 | 2002-10-03 | Taro Pharmaceutical Inductries Ltd. | Process for preparing non-hygroscopic sodium valproate composition |
ATE353633T1 (de) * | 2002-12-19 | 2007-03-15 | Pharmacia Corp | Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält |
-
2003
- 2003-12-05 AT AT03796731T patent/ATE353633T1/de not_active IP Right Cessation
- 2003-12-05 DE DE60311875T patent/DE60311875T2/de not_active Expired - Fee Related
- 2003-12-05 EP EP03796731A patent/EP1575563B1/en not_active Expired - Lifetime
- 2003-12-05 AU AU2003298010A patent/AU2003298010A1/en not_active Abandoned
- 2003-12-05 CA CA002511385A patent/CA2511385A1/en not_active Abandoned
- 2003-12-05 ES ES03796731T patent/ES2280835T3/es not_active Expired - Lifetime
- 2003-12-05 MX MXPA05006802A patent/MXPA05006802A/es unknown
- 2003-12-05 BR BR0317392-5A patent/BR0317392A/pt not_active IP Right Cessation
- 2003-12-05 WO PCT/US2003/038792 patent/WO2004060352A1/en active IP Right Grant
- 2003-12-05 JP JP2004565235A patent/JP2006513238A/ja active Pending
- 2003-12-11 EP EP03814729A patent/EP1575564A1/en not_active Withdrawn
- 2003-12-11 MX MXPA05005667A patent/MXPA05005667A/es unknown
- 2003-12-11 JP JP2004565403A patent/JP2006514052A/ja not_active Withdrawn
- 2003-12-11 CA CA002509261A patent/CA2509261A1/en not_active Abandoned
- 2003-12-11 WO PCT/US2003/039510 patent/WO2004060353A1/en not_active Application Discontinuation
- 2003-12-11 AU AU2003296948A patent/AU2003296948A1/en not_active Abandoned
- 2003-12-11 BR BR0317103-5A patent/BR0317103A/pt not_active IP Right Cessation
- 2003-12-17 AR ARP030104684A patent/AR042511A1/es unknown
- 2003-12-17 TW TW092135756A patent/TW200423971A/zh unknown
- 2003-12-18 NL NL1025069A patent/NL1025069C2/nl not_active IP Right Cessation
- 2003-12-18 US US10/741,530 patent/US20040197411A1/en not_active Abandoned
- 2003-12-18 US US10/741,526 patent/US20050013856A1/en not_active Abandoned
- 2003-12-18 AR ARP030104716A patent/AR042536A1/es unknown
- 2003-12-18 TW TW092135960A patent/TW200413006A/zh unknown
- 2003-12-19 UY UY28138A patent/UY28138A1/es not_active Application Discontinuation
- 2003-12-19 HN HN2003000417A patent/HN2003000417A/es unknown
-
2004
- 2004-01-05 PE PE2004000027A patent/PE20040972A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY28138A1 (es) | 2004-08-31 |
TW200423971A (en) | 2004-11-16 |
DE60311875D1 (de) | 2007-03-29 |
AR042536A1 (es) | 2005-06-22 |
WO2004060352A8 (en) | 2005-09-15 |
NL1025069C2 (nl) | 2005-02-16 |
ES2280835T3 (es) | 2007-09-16 |
EP1575563A1 (en) | 2005-09-21 |
MXPA05006802A (es) | 2005-09-08 |
CA2511385A1 (en) | 2004-07-22 |
AU2003296948A1 (en) | 2004-07-29 |
HN2003000417A (es) | 2005-11-01 |
EP1575563B1 (en) | 2007-02-14 |
WO2004060353A1 (en) | 2004-07-22 |
AU2003298010A1 (en) | 2004-07-29 |
PE20040972A1 (es) | 2004-12-14 |
ATE353633T1 (de) | 2007-03-15 |
JP2006513238A (ja) | 2006-04-20 |
JP2006514052A (ja) | 2006-04-27 |
WO2004060352A1 (en) | 2004-07-22 |
CA2509261A1 (en) | 2004-07-22 |
US20040197411A1 (en) | 2004-10-07 |
BR0317103A (pt) | 2005-10-25 |
TW200413006A (en) | 2004-08-01 |
WO2004060353A9 (en) | 2004-10-07 |
AR042511A1 (es) | 2005-06-22 |
DE60311875T2 (de) | 2007-08-30 |
NL1025069A1 (nl) | 2004-07-01 |
US20050013856A1 (en) | 2005-01-20 |
MXPA05005667A (es) | 2005-07-26 |
EP1575564A1 (en) | 2005-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0317392A (pt) | Formulação não-higroscópica incluindo uma droga higroscópica | |
CY1111867T1 (el) | Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη | |
BR0208338A (pt) | Derivados de piridina | |
BR0212922A (pt) | Composições farmacêuticas | |
EE200000468A (et) | Ühendid, nende kasutamine ja farmatseutiline kompositsioon | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
BR0315169A (pt) | Referência cruzada a pedidos de patente relacionados | |
ATE255909T1 (de) | Konservierungssystem für topisch verabreichbare pharmazeutische zusammensetzungen | |
DK1536836T3 (da) | Topisk emulsionsgelsammensætning indeholdende diclofenacnatrium | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
BR0307071A (pt) | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico | |
BR0314058A (pt) | Composições para cuidados pessoais a base de álcool ramificado | |
BR0215027A (pt) | Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação | |
BR0312768A (pt) | Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos | |
BR9910539A (pt) | Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol | |
TR200100455T2 (tr) | Nimesulid içeren topikal farmasötik bileşimler | |
BR0212353A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BR0317284A (pt) | Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno | |
BR0001201A (pt) | Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica | |
BRPI0417950A (pt) | composições farmacêuticas | |
BRPI0415530A (pt) | uso de compostos orgánicos | |
BRPI0418726A (pt) | naftalenossulfonato de clopidogrel cristalino ou hidrato do mesmo, método para sua preparação e composição farmacêutica contendo o mesmo | |
BR0316853A (pt) | Formulações de topiramato estáveis | |
NO20024880L (no) | Sammensetning inneholdende fosfat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADE(S), |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |